$2.84 -0.03 (%) CytRx Corp - NASDAQ

Oct. 30, 2014 | 04:00 PM

Partner Headlines

  1. CytRx Announces Publication of Phase 1b/2 Aldoxorubicin Clinical Data In Soft Tissue Sarcoma In Cancer, The Peer-Reviewed Journal Of The American Cancer Society

    Benzinga | Oct. 20, 2014 | 06:04AM EST
  2. US Stock Futures Surge Ahead Of Walgreen Earnings, Economic Data

    Benzinga | Sep. 30, 2014 | 07:19AM EST
  3. US Stock Futures Decline Ahead Of Home Sales Report

    Benzinga | Sep. 22, 2014 | 07:38AM EST
  4. US Stock Futures Flat, Apple In Focus

    Benzinga | Sep. 9, 2014 | 07:04AM EST
  5. Mid-Afternoon Market Update: Markets Turn Back As Meritor Hangs Onto Its Gains

    Benzinga | May. 1, 2014 | 15:22PM EST
  6. Mid-Day Market Update: Weight Watchers Shares Surge On Upbeat Results; JDS Uniphase Tumbles

    Benzinga | May. 1, 2014 | 12:22PM EST
  7. CytRx to Present Global Phase 2b Trial of Aldoxorubicin in Soft Tissue Sarcomas Data at ASCO

    Benzinga | Apr. 24, 2014 | 07:08AM EST
  8. Morning Market Movers

    Benzinga | Apr. 3, 2014 | 09:42AM EST
  9. CytRx Reports Positive Results from Global Phase 2b Clinical Trial with Aldoxorubicin in Advanced Soft Tissue Sarcomas

    Benzinga | Jan. 8, 2014 | 08:35AM EST
  10. Morning Market Movers

    Benzinga | Dec. 30, 2013 | 10:16AM EST
  11. Morning Market Movers

    Benzinga | Dec. 24, 2013 | 09:59AM EST
  12. Morning Market Losers

    Benzinga | Dec. 16, 2013 | 10:10AM EST
  13. Stocks Hitting 52-Week Highs

    Benzinga | Dec. 11, 2013 | 10:18AM EST
  14. Morning Market Movers

    Benzinga | Dec. 11, 2013 | 09:56AM EST
  15. A Small Cap That is Cashing In on ObamaCare

    Benzinga | Nov. 19, 2013 | 16:44PM EST
  16. CytRx Announces Further Positive Clinical Data from Global Phase 2b Aldoxorubicin Study

    Benzinga | Oct. 31, 2013 | 06:03AM EST
  17. CytRx Says Wins FDA Acceptance for Protocol of Phase 2 Aldoxorubicin in Glioblastoma Trial

    Benzinga | Oct. 23, 2013 | 08:36AM EST
  18. Edison Investment Research Comments on CytRx Corporation Following Positive Aldoxorubicin Data

    Benzinga | Oct. 10, 2013 | 11:16AM EST
  19. Morning Market Losers

    Benzinga | Oct. 9, 2013 | 09:59AM EST
  20. Benzinga's Top Pre-Market Losers

    Benzinga | Oct. 9, 2013 | 08:20AM EST
  21. CytRx Prices 10M Share Offering at $2.25/Share

    Benzinga | Oct. 9, 2013 | 06:00AM EST
  22. Stocks To Watch For October 9, 2013

    Benzinga | Oct. 9, 2013 | 04:22AM EST
  23. CytRx Announces Proposed Public Offering of Common Stock

    Benzinga | Oct. 8, 2013 | 16:24PM EST
  24. CytRx's Reports Aldoxorubicin Data Demonstrates Advantages over Doxorubicin

    Benzinga | Sep. 30, 2013 | 06:05AM EST
  25. CytRx Corp. Reports Operating Results (10-Q)

    GuruFocus | Nov. 9, 2012 | 03:04AM EST
  26. CytRx Closes Offering of 9.2M Shares

    Benzinga | Oct. 24, 2012 | 02:39AM EST
  27. CytRx Announces Exercise of Underwriters' Over-Allotment Option

    Benzinga | Oct. 19, 2012 | 06:18AM EST
  28. CytRx Prices 8M Share Offering at $2.50/Share

    Benzinga | Oct. 17, 2012 | 15:22PM EST
  29. CytRx Announces Proposed Public Offering of Common Stock

    Benzinga | Oct. 17, 2012 | 10:50AM EST
  30. CytRx's Aldoxorubicin Clinical Data Presented at the ESMO 2012 Congress

    Benzinga | Oct. 1, 2012 | 02:37AM EST
  31. UPDATE: Rodman & Renshaw Initiates CytRx Corporation at Buy

    Benzinga | Sep. 10, 2012 | 00:54AM EST
  32. From Earlier: CytRx Announces Favorable Results from Phase 1b/2 Clinical Trial with INNO-206

    Benzinga | Jun. 4, 2012 | 02:19AM EST
  33. Weekly CEO Buys Highlight: ULBI, BDE, ALNY, CTTR, GFN

    GuruFocus | Feb. 27, 2012 | 04:27AM EST
  34. Weekly CFO Buys Highlight: CYTR, PZZI, AGYS, PLBC

    GuruFocus | Feb. 27, 2012 | 03:23AM EST
  35. Sickle Cell Knocks Out NFL Player. Can these Companies Help?

    Benzinga | Jan. 4, 2012 | 05:41AM EST
Trading Center